關於 cookie 的說明

本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。

搜尋結果Search Result

符合「Personnel announcements」新聞搜尋結果, 共 742 篇 ,以下為 1 - 24 篇 訂閱此列表,掌握最新動態
BMO Announces Election of Board of Directors

TORONTO, April 17, 2024 /PRNewswire/ -- Bank of Montreal (TSX:BMO) (NYSE:BMO) today held its Annual Meeting of Shareholders. At the meeting, all director nominees listed in the bank's management proxy circular dated February 7, 2024 were elected. The detailed results of the vote for the election of directors are set out below. Each of the following 13 nominees was elected as a director of Bank of Montreal: Nominee Votes For Votes Withheld Janice MBabiak 342,157,861 97.36 % 9,271,842 2.64 % Craig WBroderick 347,929,389 99.00 % 3,500,313 1.00 % Hazel Claxton 350,277,619 99.67 % 1,152,183 0.33 % George A. Cope 334,780,073 95.26 % 16,649,729 4.74 % Stephen Dent 350,489,694 99.73 % 939,655 0.27 % Christine A. Edwards 340,920,673 97.01 % 10,508,676 2.99 % Martin S. Eichenbaum 349,808,876 99.54 % 1,620,472 0.46 % David Harquail 350,281,227 99.67 % 1,148,121 0.33 % Linda S. Huber 350,224,200 99.66 % 1,205,559 0.34 % Eric R. La Flèche 346,253,767 98.53 % 5,176,036 1.47 % Lorraine Mitchelmore 347,954,785 99.01 % 3,474,973 0.99 % MadhuRanganathan 318,658,988 90.68 % 32,770,815 9.32 % Darryl White 349,208,736 99.37 % 2,221,067 0.63 % Final voting results on all matters voted on at the Annual Meeting of Shareholders held earlier today will be published shortly on www.bmo.com, and filed with Canadian and U.S. securities regulators.   About BMO Financial GroupBMO Financial Group is the eighth largest bank in North America by assets, with total assets of $1.3 trillion as of January 31, 2024. Serving customers for 200 years and counting, BMO is a diverse team of highly engaged employees providing a broad range of personal and commercial banking, wealth management, global markets and investment banking products and services to 13 million customers across Canada, the United States, and in select markets globally. Driven by a single purpose, to Boldly Grow the Good in business and life, BMO is committed to driving positive change in the world, and making progress for a thriving economy, sustainable future, and inclusive society. Internet: www.bmo.com                                Twitter: @BMOMedia For News Media Inquiries: John Fenton, Toronto, john.fenton@bmo.com, (416) 867-3996; For Investor Relations Inquiries: Christine Viau, Head, Investor Relations, Toronto, christine.viau@bmo.com, (416) 867-6956, Bill Anderson, Director, Investor Relations, Toronto, Bill2.Anderson@bmo.com, (416) 867-7834

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 263 加入收藏 :
The Channel Company Announces New Chief Revenue Officer Wayne Silverman

WESTBOROUGH, Mass., April 17, 2024 /PRNewswire/ -- The Channel Company, a global provider of news, insights, strategy, events, and marketing services for the information technology industry, announced today that Wayne Silverman has joined the executive team as Chief Revenue Officer. Silverman will lead all aspects of The Channel Company's worldwide revenue growth initiatives, sales strategy innovation, and customer engagement. Silverman joins The Channel Company most recently from Spiceworks Ziff Davis (SWZD), where he served as Chief Revenue Officer. He also brings more than 25 years of digital media, technology, SaaS, and big data experience within global roles. Silverman has driven revenue innovation and growth across prominent companies including CBS, Dun & Bradstreet, International Data Group (IDG), CNET, and Business.com where he held senior leadership positions.  "We are thrilled to welcome Wayne to the team," said Matthew Yorke, CEO of The Channel Company. "His global expertise within the technology and digital media industries alongside his unwavering dedication to customer experience will continue to elevate how we deliver for our clients and drive expanded opportunities for our organization." "It's a privilege to step into the role of CRO at The Channel Company during such a pivotal period for the company," Silverman stated. "As we look ahead, the tech sector is poised for a transformation with artificial intelligence taking center stage. The Channel Company, with its esteemed media outlets, signature events, and expert marketing and consulting offerings, will be instrumental for our partners, clients, and the entire tech community. I am eager to collaborate with the talented team here at The Channel Company to deliver innovative, outcome-driven services to our clients as this market evolves." About The Channel Company The Channel Company, Inc. is the global leader in data-driven growth acceleration solutions and services for the IT channel. With 40+ years of channel expertise and a premier portfolio of editorial brands, marketing and event services, and strategic consulting, we help technology vendors, solution providers, and IT decision-makers worldwide unlock better business outcomes. The Channel Company is a portfolio company of investment funds managed by EagleTree Capital, a New York City-based private equity firm. For more information, visit thechannelco.com.    About EagleTree Capital: EagleTree Capital is a leading New York-based middle-market private equity firm, with over $5.6 billion of assets under management, that has completed over 40 private equity investments and over 95 add-on transactions over the past 20+ years. EagleTree primarily invests in North America in the following sectors: media and business services, consumer, and water and specialty industrial. For more information, visit www.eagletree.com or find EagleTree on LinkedIn. Media contact: Corporate Communications, corporatecommunications@thechannelco.com  

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 284 加入收藏 :
Former Bosch Radar Lead Joins Altos Radar to Accelerate its 4D Imaging Radar Technology

Altos Radar appoints Dr. Mingkang Li as President to lead development of its radar applications and European market development. Dr. Li formerly led Bosch Germany's next generation imaging radar group. Dr. Li's addition to Altos Radar, renowned for its breakthrough 4D imaging radar solutions, underscores the company's rapid rise and market influence. LOS ALTOS, Calif., April 16, 2024 /PRNewswire/ -- In a significant industry move, former head of next-generation Imaging Radar technology at Bosch (Germany), Dr. Mingkang Li, has been appointed President at 4D imaging radar tech startup Altos Radar. Effective April 11, Dr. Li will oversee development of Altos' 4D millimeter wave radar products while also spearheading market expansion efforts in Europe. Dr. Li brings nearly a decade of experience in high-performance radar research and development from Bosch, the world's largest supplier of automotive parts. Before joining Altos Radar, Dr. Li led the technical development team of its next-generation millimeter-wave radars at Bosch's headquarters in Germany, comprising several groups, including hardware, software, signal processing algorithms and embedded implementation. Dr. Mingkang Li Dr. Li holds a bachelor's and master's degree from Tongji University and RWTH Aachen University respectively and earned his Ph.D. through a collaborative program between Bosch's radar pre-development department and the Technical University of Braunschweig. Altos Radar CEO, Li Niu, hailed Dr. Li as a rare leader in the field of radars, praising his technical depth, extensive automotive industry experience, and entrepreneurial spirit. "Altos Radar is committed to advancing the development and implementation of imaging radar technology, which, in our opinion, will be the game changer in high-level Advanced Driver-Assistance Systems (ADAS). Dr. Li's expertise in automotive radars will not only enhance our capabilities but also significantly propel our engineering endeavors going forward." Founded in January 2023 by veterans of leading tech firms including Apple, Pony.ai and Mozilla, Altos Radar secured prompt backing from notable investors - led by Hesai CEO David (Yifan) Li, ZhenFund and Monad Ventures - before quickly launching a number of high-performance 4D imaging products to the automotive market, causing a ripple in the industry. Now, the onboarding of Dr. Li only further validates the strength of both the team and product. Dr. Li has been particularly impressed by both Altos Radar's engineering capabilities and product performance, noting the exceptional quality of its point cloud compared to that of other products on the market. "The point clouds from Altos Radar stand out due to their high density, minimal noise, long detection range and accurate height measurement." Besides, he notes that the point clouds shown by other radar companies are often collected by multiple radars and rely on excessive post-processing. "These point clouds are untrue representations and of little practical value. However, Altos' demo showcases an optimal balance in the whole radar system between channel quantity, antenna array design, waveform design, signal processing and embedded implementation." At CES 2024 in Las Vegas, Altos Radar unveiled its V series, the world's first 4-chip cascaded 4D imaging radar based on the TI TDA4 platform. The product combines exceptional performance, low cost, high reliability, and ease of mass production, positioning it as a strong contender against lidar technology. Altos Radar's products are already undergoing testing and pre-production preparation with several global automakers, autonomous driving companies and robotics firms, with large-scale deployment expected soon. According to IDTechEx's 2024-2044 automotive radar report, 70% of new cars in 2022 were equipped with front radars and 30% with side-facing radars. As ADAS technology evolves and Level 3 autonomous driving systems become more available, the uptake of 4D imaging radars is on the rise. About Altos Radar With extensive experience in the autonomous driving industry, Altos Radar is a rising tech startup developing high-performance 4D imaging radars at a fraction of the cost of its competitors. Altos Radar's core team comprises top talents from the tech industry, including seasoned professionals in hardware from Apple and Huawei, as well as software experts from Mozilla and Pony.ai. Product Video: https://youtu.be/2x2Z-wPCxt0  https://youtu.be/6j7tMGT77Co  For more information, please visit https://www.altosradar.com/ 

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 171 加入收藏 :
P&G Appoints Neal Reed as Senior Vice President and Managing Director, P&G Australia and New Zealand

SYDNEY, April 16, 2024 /PRNewswire/ -- The Procter & Gamble Company (NYSE: PG) has appointed Neal Reed as Senior Vice President and Managing Director, P&G Australia and New Zealand. He succeeds Kumar Venkatasubramanian, who will return to India to lead the P&G India Business.   Under Kumar's leadership, P&G Australia and New Zealand delivered record metrics, category growth and strong retailer partnerships. He has also championed Equality and Inclusion, expanding impactful citizenship programs for employees and communities, including P&G ANZ's partnership with the Sydney Gay and Lesbian Mardi Gras. Reed joined P&G over 28 years ago, starting his career as an Account Rep in the UK. He spent 14 years working in a broad range of Sales assignments across the UK, Europe, Middle East and Africa. He successfully led Fabric Care Europe before moving to Japan in 2016. In his most recent assignment as Senior Vice President Oral Care, Greater China, Reed's leadership enabled the business to thrive with continued growth via his commitment to elevated consumer experience. "I am excited for the opportunity to lead a dynamic ANZ Team." says Reed "I'm passionate about inspiring and developing the organisation through our integrated growth strategy." Stanislav Vecera, P&G president, Asia Pacific, Middle East, and Africa said, "I want to thank Kumar for his strong leadership of the ANZ organisation, I know he will continue to excel in his newly appointed role to lead P&G India. I am thrilled with Neal's appointment as Senior Vice President and Managing Director, Australia and New Zealand. He brings a wealth of knowledge and global experience that will build the organisation and support strong business results."    About Procter & Gamble P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always Discreet®, Ambi Pur®, Downy®, Fairy®, Febreze®, Gillette®, Head & Shoulders®, Herbal Essences®, Metamucil®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Vicks®, and Voost®. The P&G community includes operations in approximately 70 countries worldwide. Please visit www.pg.com for the latest news and information about P&G and its brands.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 90 加入收藏 :
Warehouse Wonders in AR: SSI Schaefer Builds the Future of Logistics at KOREA MAT 2024

Key highlights: Augmented Reality App at SSI Schaefer's booth (Booth 10C111) allows visitors to visualize their dream warehouse Mr. Albert Choi, recently appointed as SSI Schaefer's Country Manager of Korea, and Mr. Carsten Spiegelberg, Head of Logistics Solutions - APAC MEA, will share their insights and expertise during the exclusive 'Optimizing Cold Chain Warehouse Intralogistics for Efficiency and Precision' seminar SEOUL, South Korea, April 16, 2024 /PRNewswire/ -- SSI Schaefer, a renowned global leader in intralogistics and automated warehousing, is announcing its participation at KOREA MAT 2024 (April 23-26). Visitors to SSI Schaefer's booth (Booth 10C111 in KINTEX 2) will have the chance to experience the future of logistics solutions and envision their own warehouse scenarios using augmented reality (AR). To pre-book a one-on-one consultation with an SSI Schaefer expert, please visit: https://campaigns.ssi-schaefer.com/en-kr/koreamat-2024-signup "As a digital, future-ready tool itself, the AR App lets our customers envision automated, digitalized facilities while embodying our commitment to technological innovation — from our customer experiences to our warehouse solutions," commented Mr. Albert Choi, Country Manager of SSI Schaefer Korea. "I'm thrilled to be spending my first KOREA MAT as head of SSI Schaefer Korea by helping our customers explore possibilities in this innovative way." Embracing the theme of "Warehouse Wonders: Building the Future of Logistics" at the event this year, visitors to SSI Schaefer's booth can use the AR App to explore scenarios and advanced technology in facilities across different parameters, testing various solutions that can make their warehouse visions a reality. To guide visitors in achieving their desired warehouse setup, SSI Schaefer consultants will leverage their expertise to provide customized recommendations and practical solutions aligned with business objectives. To further engage visitors, the booth will have interactive displays that illustrate how SSI Schaefer has addressed various intralogistics challenges with tailored warehouse solutions, ranging from semi-automated to fully automated facilities. In-depth case study videos will spotlight successful implementations worldwide, providing firsthand insights into the effectiveness of SSI Schaefer's solutions. Further demonstrating its commitment to the latest technologies, SSI Schaefer's booth will highlight its comprehensive suite of innovations, including cutting-edge IT solutions like WAMAS® software that digitalizes and future-proofs warehouse operations. Visitors can also witness a range of prestigious awards and recognitions earned by SSI Schaefer over the years, underscoring the company's longstanding dedication to excellence. Specific to refrigerated logistics, Mr. Choi and Mr. Carsten Spiegelberg, Head of Logistics Solutions – SSI Schaefer APAC MEA, will share their expertise in an exclusive seminar titled 'Optimizing Cold Chain Warehouse Intralogistics for Efficiency and Precision' on April 25. Attendees will have the opportunity to explore strategies for energy-efficient and space-optimized cold storage facilities, including innovative automation systems and material flow techniques. They will learn essential practices for maintaining stable temperatures critical to preserving perishable goods while minimizing energy consumption. In addition, attendees will gain insight into how to accommodate greater inventory volumes without the need for extensive expansion, ensuring competitiveness in the evolving cold-chain market. For more information on the event, please visit: https://www.ssi-schaefer.com/en-asia/newsroom/events/korea-mat-2024-1776000   About SSI Schaefer The SSI Schaefer Group is a leading global solution provider for all areas of intralogistics. With innovative technologies and software, the company empowers small to medium-sized enterprises as well as large companies to increase the efficiency and sustainability of their storage, picking, and transport processes -- offering complete solutions spanning fully automated warehouses with tailored service and maintenance packages, to robotics and automated guided vehicles, to manual and semi-automatic systems such as workstations, racks, and containers. For further information, please visit SSI Schaefer's newly updated website https://www.ssi-schaefer.com/en-asia

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 100 加入收藏 :
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)

SAN FRANCISCO and SUZHOU, China, April 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces the appointment of Dr. Nageatte Ibrahim, a world-famous Oncology Clinical Development Leader in the Pharmaceutical Industry, as the Oncology CMO. Dr. Ibrahim will provide the strategy, execution and leadership for the Oncology Global Clinical Development program. Dr. Nageatte Ibrahim has over 11 years of oncology industry drug development experience at Merck and GSK. Dr. Ibrahim also has 9 years of faculty appointments; an Instructor of Medicine at Harvard Medical School and attending physician at Dana-Farber Cancer Institute and later an Adjunct Assistant Professor at Perlman School of Medicine/Abramson Cancer Center.  Dr. Ibrahim's fore into industry began at GSK working on the dabrafenib/trametinib program and global approvals in melanoma. Prior to joining Innovent, Dr. Ibrahim was the Vice President, Global Clinical Development, Oncology at Merck, overseeing the strategy and execution for Keytruda and combinations across multiple tumor types and assets. In her early career at Merck, she led the pivotal global registration studies for Keytruda in front-line advanced melanoma and resectable melanoma which have been approved globally. Major accomplishments from Dr. Ibrahim's clinical development teams under her leadership include global approvals in Merkel cell, gastric, biliary, and hepatocellular cancers, resected Stage IIB or IIC melanoma, pediatric neurofibromatosis-1 (NF-1) as well as tumor agnostic indications for TMB-H expressing cancers and MSI-H/dMMR tumors. Dr. Ibrahim was also responsible for the development strategy of multiple assets, including in partnership with other companies, while at Merck. Dr. Ibrahim has a long and successful track record of building great teams, fostering an environment of learning and comradery, as well as mentoring and coaching future talent for leadership. She has also served as the Scientific Advisor for the Melanoma Research. Dr. Nageatte Ibrahim earned her B.S. in Molecular Biology and Biochemistry from Rutgers University and M.D. from MCP-Hahnemann/Drexel College of Medicine. Dr. Ibrahim completed an internal medicine residency at MCP-Hahnemann/Drexel College of Medicine, a Hematology and Oncology Fellowship from Tufts Medical Center, and Oncology Research Fellowship at Massachusetts General Hospital. Dr. Ibrahim possesses a Pennsylvania Medical License and ABIM Certification in Medical Oncology. "We are very excited to welcome Dr. Nageatte Ibrahim onboard as our Oncology CMO in Global Clinical Development," said Dr. Michael Yu, Founder, Chairman and CEO of Innovent. "Dr. Ibrahim has extensive experience in global clinical development in oncology along with excellent leadership skills. We believe that with Dr. Ibrahim joining Innovent, her talent and innovation will further enhance our clinical development capabilities in oncology, solidify our efforts in building a global clinical development platform and an international clinical team, develop a more innovative and cutting-edge pipeline with global First-in-Class and Best-in Class agents, and accelerate the innovation pace globally. Dr. Nageatte Ibrahim will bring new momentum to reach Innovent's goal 'to be one of the world's leading biopharmaceutical companies.'" "Innovent is a rapidly growing and cutting-edge biopharmaceutical company," said Dr. Ibrahim. "I am delighted to join such a company with a strong emphasis on science and innovation to bring new cancer treatments forward efficiently. There are many talented and passionate people at Innovent who strive to make great medicines that benefit patients around the world, and I am honored to join them in this quest." About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to provide high-quality biologics that are affordable to all. The company discovers, develops, manufactures and commercializes innovative medicines that treat some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has 10 products in the market, 3 new drug applications under the NMPA review, 5 assets in Phase III or pivotal clinical trials and 18 more molecules in early clinical stage. Innovent partners with over 30 global healthcare leaders, including Eli Lilly, Roche, Sanofi, Adimab, Incyte and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn. Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s). Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 319 加入收藏 :
首 頁 我的收藏 搜 尋 新聞發佈